Miglitol, an Oral Antidiabetic Drug, Downregulates Melanogenesis in B16F10 Melanoma Cells through the PKA, MAPK, and GSK3β/β-Catenin Signaling Pathways

Hyperpigmentation is a common condition that causes darker spots or patches on the skin, which often look brown, black, gray, red, or pink. This results in unresolved psychological impact due to high anxiety, depression, and somatoform disorder. We aimed to repurpose an antidiabetic drug, miglitol, as an effective compound against hyperpigmentation when applied as a cosmeceutical agent. The present study investigated the antimelanogenic effects of miglitol and the trehalase inhibitor validamycin A. Miglitol in isolation exhibited no cytotoxicity and significantly reduced the melanin production and intracellular tyrosinase activity in B16F10 melanoma cells. The Western blotting results showed that miglitol reduces the expression of melanogenic regulatory factors, including tyrosinase, tyrosinase-related protein (TRP)-1, TRP-2, and microphthalmia-associated transcription factor (MITF). Mechanistically, miglitol appears to suppress melanin synthesis through cAMP-dependent protein kinase (PKA)-dependent downregulation of MITF, a master transcription factor in melanogenesis. The antimelanogenic effects of miglitol was mediated by downregulation of the p38 signaling pathway and upregulation of extracellular signal-regulated kinase (ERK). Moreover, miglitol decreases P-GSK3β and β-catenin levels compared to those in the untreated group. However, miglitol activated P-β-catenin expression compared to that in the untreated group. Finally, we tested the potential of miglitol in topical application through primary human skin irritation tests on the normal skin (upper back) of 33 volunteers. In these assays, miglitol (125 and 250 μM) did not induce any adverse reactions. Taken together, these findings suggest that the regulation of melanogenesis by miglitol may be mediated by the PKA, MAPK, and GSK3β/β-Catenin signaling pathways and that miglitol might provide new insights into drug repurposing for the treatment of hyperpigmentation symptoms.

[1]  C. Elmets,et al.  Neuroendocrine signaling in the skin with a special focus on the epidermal neuropeptides. , 2022, American journal of physiology. Cell physiology.

[2]  S. Singhal,et al.  Drug Repurposing Strategies for Non-Cancer to Cancer Therapeutics. , 2022, Anti-cancer agents in medicinal chemistry.

[3]  T. Sarna,et al.  Melanoma, Melanin, and Melanogenesis: The Yin and Yang Relationship , 2022, Frontiers in Oncology.

[4]  J. Argüelles,et al.  TREHALASE INHIBITION BY VALIDAMYCIN A MAY BE A PROMISING TARGET TO DESIGN NEW FUNGICIDES AND INSECTICIDES. , 2021, Pest management science.

[5]  Na Zhao,et al.  Schisandrin B inhibits α-melanocyte-stimulating hormone-induced melanogenesis in B16F10 cells via downregulation of MAPK and CREB signaling pathways. , 2020, Bioscience, biotechnology, and biochemistry.

[6]  C. Hyun,et al.  Inhibitory Effects of Pinostilbene Hydrate on Melanogenesis in B16F10 Melanoma Cells via ERK and p38 Signaling Pathways , 2020, International journal of molecular sciences.

[7]  Spencer J. Williams,et al.  α-glucosidase inhibitors as host-directed antiviral agents with potential for the treatment of COVID-19. , 2020, Biochemical Society transactions.

[8]  C. Yompakdee,et al.  Fermented Unpolished Black Rice (Oryza sativa L.) Inhibits Melanogenesis via ERK, p38, and AKT Phosphorylation in B16F10 Melanoma Cells , 2020, Journal of microbiology and biotechnology.

[9]  M. Goto,et al.  The alpha-glucosidase inhibitor miglitol increases hepatic CYP7A1 activity in association with altered short-chain fatty acid production in the gut of obese diabetic mice , 2020, Metabolism open.

[10]  A. Nishikawa,et al.  Anti-melanogenic activity of salacinol by inhibition of tyrosinase oligosaccharide processing. , 2019, Journal of biochemistry.

[11]  N. Tanaka,et al.  Miglitol attenuates non‐alcoholic steatohepatitis in diabetic patients , 2018, Hepatology research : the official journal of the Japan Society of Hepatology.

[12]  P. Wingfield,et al.  Membrane-associated human tyrosinase is an enzymatically active monomeric glycoprotein , 2018, PloS one.

[13]  Seung Eun Lee,et al.  Anti-melanogenic effects of resorcinol are mediated by suppression of cAMP signaling and activation of p38 MAPK signaling , 2018, Bioscience, biotechnology, and biochemistry.

[14]  K. Node,et al.  α-Glucosidase inhibitor miglitol attenuates glucose fluctuation, heart rate variability and sympathetic activity in patients with type 2 diabetes and acute coronary syndrome: a multicenter randomized controlled (MACS) study , 2017, Cardiovascular Diabetology.

[15]  T. R. Lee,et al.  The synergistic effect of maltose enhances the anti-melanogenic activity of acarbose , 2017, Archives of Dermatological Research.

[16]  Shumpei Asamizu Biosynthesis of nitrogen-containing natural products, C7N aminocyclitols and bis-indoles, from actinomycetes , 2017, Bioscience, biotechnology, and biochemistry.

[17]  T. R. Lee,et al.  International Journal of Molecular Sciences the Development of Sugar-based Anti-melanogenic Agents , 2022 .

[18]  H. Hosoi,et al.  Review: Miglitol has potential as a therapeutic drug against obesity , 2015, Nutrition & Metabolism.

[19]  Chao-Hsun Yang,et al.  Fenofibrate suppresses melanogenesis in B16-F10 melanoma cells via activation of the p38 mitogen-activated protein kinase pathway. , 2013, Chemico-biological interactions.

[20]  T. R. Lee,et al.  Novel inhibitory effect of the antidiabetic drug voglibose on melanogenesis , 2013, Experimental dermatology.

[21]  G. Kokil,et al.  Development and Discovery Avenues in Bioactive Natural Products for Glycemic Novel Therapeutics , 2013 .

[22]  Myeon-Hyeon Wang,et al.  Involvement of the p38 MAPK and ERK signaling pathway in the anti-melanogenic effect of methyl 3,5-dicaffeoyl quinate in B16F10 mouse melanoma cells. , 2012, Chemico-biological interactions.

[23]  H. H. Park,et al.  Inhibition of melanogenesis by 5,7-dihydroxyflavone (chrysin) via blocking adenylyl cyclase activity. , 2011, Biochemical and biophysical research communications.

[24]  M. Ichihashi,et al.  Approaches to identify inhibitors of melanin biosynthesis via the quality control of tyrosinase. , 2007, The Journal of investigative dermatology.

[25]  D. Tobin,et al.  Melanin pigmentation in mammalian skin and its hormonal regulation. , 2004, Physiological reviews.